Upgrade to SI Premium - Free Trial

Merck (MRK) Announces FDA Approves KEYTRUDA plus LENVIMA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

September 18, 2019 6:21 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles